The temperature cycling test passed. The humidity soak passed. The accelerated aging study completed on schedule. Then the product went to the notified body, and the first question was about the packaging validation.
The packaging validation had not been done. The device had been tested. The packaging that maintained sterility through shipping, handling, and storage had not.
Medical device environmental testing is not a single discipline with a single standard. It is two parallel disciplines — device testing and packaging testing — governed by different standards, assessed by different parts of the regulatory submission, and requiring different chamber configurations. Missing either one doesn't produce a partial qualification. It produces a failed submission.
The two standards that govern almost everything
IEC 60068 is the device's environmental qualification standard. It specifies test methods for temperature cycling, thermal shock, damp heat, vibration, mechanical shock, and the other environmental stresses the device itself must survive. Most of its test methods appear in medical device technical files under references to specific product standards that cite IEC 60068 methods — IEC 60601-1 for electrical medical equipment, ISO 14971 for risk management, and the device-specific standards that apply to the product category in question.
ISO 11607 governs sterile medical device packaging. It defines requirements in two parts: ISO 11607-1 covers materials, sterile barrier systems, and packaging systems; ISO 11607-2 covers the validation of forming, sealing, and assembly processes. Both parts are FDA-recognised consensus standards and harmonised standards under the EU Medical Device Regulation (MDR), making them effectively mandatory for any device that must maintain sterility between manufacture and point of use. The FDA and the EU treat ISO 11607 compliance as a prerequisite for market access, not a recommendation.
A medical device that passes IEC 60068 device testing has demonstrated that the device survives environmental stress. It has said nothing about whether the packaging that the device ships in maintains the sterile barrier through the same distribution environment. These are separate validation activities, both required, and they require different test protocols, different specimens, and sometimes different chamber configurations.
What ISO 11607 actually requires from environmental testing
ISO 11607 requires that the packaging system be tested under the environmental and distribution conditions it will actually encounter — not generic conditions, but the specific conditions of the supply chain from manufacturer to end user. The standard references over 100 test methods in its Annex B, drawn from ISO, ASTM, ISTA, and other organisations, covering temperature and humidity cycling, accelerated aging, distribution simulation, and seal integrity.
The accelerated aging requirement is where environmental chambers become directly relevant. ISO 11607 requires validation of shelf-life claims — the period during which the packaging maintains the sterile barrier. Demonstrating shelf life through real-time aging takes as long as the claimed shelf life, which may be two to five years. Accelerated aging, typically following ASTM F1980, uses elevated temperature to predict the equivalent real-time aging in a fraction of the time. A product claiming a three-year shelf life at room temperature can validate that claim using an accelerated aging study at elevated temperature, with the acceleration factor derived from the Arrhenius equation.
The chambers used for accelerated aging of medical device packaging are humidity-controlled incubators or stability chambers held at elevated temperatures — typically 40°C, 50°C, or 60°C — with appropriate humidity control where the packaging material is moisture-sensitive. The chamber requirements are similar to pharmaceutical stability chambers in precision and data logging capability, but the temperature setpoints are typically higher and the humidity control requirements are defined by the packaging material characteristics rather than by a standard's fixed conditions.
The distribution simulation test that most labs run incorrectly
ISO 11607 requires that packaging survive the distribution environment — the actual physical stresses of transport, handling, and storage between manufacture and point of use. ISTA (International Safe Transit Association) test protocols are the most commonly referenced methods for distribution simulation, with ISTA 2A and ISTA 3A covering general distribution for packaged products up to 68kg.
The distribution simulation test involves vibration, drop testing, and compression loading — the sequence and severity determined by the ISTA protocol. Temperature and humidity conditioning of the samples before and during testing may be required depending on the protocol and the packaging materials. The combination of temperature conditioning and mechanical testing requires either a vibration system inside a climatic chamber, or sequential conditioning in a chamber followed by immediate mechanical testing with a defined time limit between the two.
The sequencing matters more than most labs account for. ISTA protocols specify conditioning times and temperatures, and some protocols specify that mechanical testing must begin within a defined interval after conditioning ends — because the packaging's mechanical properties change as it comes back to ambient temperature. Running the conditioning correctly and then leaving the samples to equilibrate while equipment is set up produces a different result from running the protocol as written. The test report needs to document the actual sequence, timing, and conditions — not just "ISTA 2A conducted."
Accelerated aging: what the Arrhenius equation and Q10 factors actually mean for your shelf-life claim
ASTM F1980 is the standard guide for accelerated aging of sterile medical device packages. Its core calculation uses the Arrhenius reaction rate model to relate the aging rate at elevated temperature to the aging rate at the reference storage temperature. The Q10 method, a simplified version commonly used in practice, assumes that the reaction rate doubles for every 10°C increase in temperature — a Q10 factor of 2.
A product claiming a two-year shelf life at 23°C can be tested using accelerated aging at 55°C. With a Q10 of 2, the acceleration factor at 55°C relative to 23°C is 2^((55-23)/10) = 2^3.2 ≈ 9.2. A two-year shelf life at 23°C is equivalent to approximately 79 days at 55°C under this model. Run the packaging through 79 days at 55°C, then test the seal integrity and sterile barrier — if it passes, the two-year shelf-life claim is supported.
The limitation that ASTM F1980 makes explicit: the Q10 = 2 assumption is a model, not a measured property of the specific packaging materials being tested. If the actual degradation mechanism for those materials has a different temperature sensitivity, the model will produce an incorrect result. For packaging materials with known temperature sensitivity data — published literature, supplier data, or prior testing — using material-specific activation energy values produces a more defensible result than the default Q10 = 2 assumption. The standard recommends using material-specific data where available, but the default is used in practice because it is conservative and defensible to regulators without requiring additional material testing.
IEC 60068 device testing for medical applications: what changes from industrial use
IEC 60068 test methods are used across consumer electronics, automotive, aerospace, and industrial applications, as well as medical devices. The methods themselves don't change between applications — temperature cycling Test Nb is the same regardless of whether the DUT is a circuit board in an automobile or an implantable device. What changes is how the test conditions are derived and what the acceptance criteria are.
For medical devices, test conditions are typically derived from the device's intended use environment and its risk assessment under ISO 14971. A device intended for hospital operating room use has a different environmental profile than one intended for home use, ambulance transport, or outdoor emergency use. The test plan must document the basis for the chosen conditions — not just cite a standard's default values, but justify why those conditions represent the actual deployment environment of this specific device.
Acceptance criteria for medical devices also differ from industrial applications in one important respect: the relevant criterion is often "does the device continue to perform its medical function within specification" rather than the broader "does it survive the test." A device that survives thermal cycling but has a measurable drift in a sensor output that was within specification before testing and outside specification after testing has failed the medical acceptance criterion even if it mechanically survived. Defining the acceptance criteria for every measurement parameter before testing begins — not after seeing the results — is both the regulatory requirement and the only way to run a test plan that means anything.
The intersection of medical device testing standards, packaging validation, and regulatory submission requirements is covered in more depth in the test plan writing guide and the documentation requirements article. For the chamber selection aspects of pharmaceutical and medical device testing, the pharmaceutical stability testing article covers the stability chamber requirements that overlap between pharma and medical device applications.
EU MDR and what changed for medical device environmental testing after 2021
The EU Medical Device Regulation (MDR 2017/745), which replaced the Medical Device Directive (MDD 93/42/EEC) with full application from May 2021, increased the evidence requirements for medical device technical files in ways that directly affect environmental testing programmes. The MDR requires manufacturers to demonstrate device performance across the full intended use conditions and throughout the device's claimed service life — which for implantable devices may extend to decades, and for reusable instruments requires evidence across the validated number of reprocessing cycles.
The most visible change for environmental testing programmes is the requirement for post-market clinical follow-up (PMCF) and post-market surveillance (PMS) data to actively confirm that real-world performance matches pre-market claims. If field data shows that devices are experiencing environmental failures not predicted by pre-market testing, the MDR framework requires manufacturers to update their testing evidence — not just track the field data. Pre-market environmental testing under MDR is no longer a one-time qualification event; it is the beginning of a continuous evidence chain that the manufacturer must maintain throughout the device's market lifetime.
For laboratories designing environmental testing programmes for EU-market devices, this means the test plan and records need to be structured for long-term accessibility and traceability from the start, not designed purely around the initial submission deadline. The test record documentation guide covers the retention and traceability requirements that MDR-driven programmes now need to build in from day one.